Minerva Advisors’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Minerva Advisors’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-26,549	Closed	-$84.7K	–	64
2023 Q2	$84.7K	Sell	26,549 -7,466	-22%	-$26.3K	0.06%	64
2023 Q1	$112K	Hold	34,015	–	–	0.08%	64
2022 Q4	$122K	Hold	34,015	–	–	0.09%	62
2022 Q3	$301K	Hold	34,015	–	–	0.23%	56
2022 Q2	$256K	Hold	34,015	–	–	0.18%	59
2022 Q1	$321K	Hold	34,015	–	–	0.21%	56
2021 Q4	$236K	Hold	34,015	–	–	0.14%	64
2021 Q3	$321K	Buy	+34,015	New	+$319K	0.19%	61

Other funds holding LUMO

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acuitas Investments Seattle, Washington $1.43M AUM 17.52% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

GWM

Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Minerva Advisors's LUMO Position: Q3 2023 in Review

Minerva Advisors sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2023, closing a stake of 26,549 shares — an estimated $84.7K sold.

Minerva Advisors first reported a position in LUMO in Q3 2021 and held it in 8 quarters. The position peaked at $321K in Q1 2022. 33 funds tracked by Wall St. Rank hold LUMO as of Q3 2023.

Minerva Advisors reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Minerva Advisors sold 26,549 Lumos Pharma, Inc. Common Stock shares in Q3 2023, an estimated $84.7K.
Minerva Advisors first reported a position in Lumos Pharma, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Minerva Advisors's Lumos Pharma, Inc. Common Stock position peaked at $321K in Q1 2022.
33 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2023.

Based on Minerva Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.